Q2 EPS Estimate for Cogent Biosciences Raised by Analyst

Cogent Biosciences, Inc. (NASDAQ:COGT) – Analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued on Tuesday, May 20th. HC Wainwright analyst R. Burns now anticipates that the technology company will post earnings per share of ($0.58) for the quarter, up from their prior estimate of ($0.66). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.24) EPS and FY2026 earnings at ($2.09) EPS.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.04.

Other equities analysts have also recently issued research reports about the stock. Piper Sandler upgraded shares of Cogent Biosciences to a “strong-buy” rating in a research report on Friday, March 7th. Scotiabank began coverage on Cogent Biosciences in a research report on Friday, March 7th. They set a “sector outperform” rating and a $17.00 price objective on the stock. Wedbush reiterated a “neutral” rating and set a $11.00 target price on shares of Cogent Biosciences in a report on Tuesday, February 25th. Robert W. Baird lowered their target price on Cogent Biosciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cogent Biosciences in a research report on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Cogent Biosciences Trading Down 0.6%

Shares of NASDAQ COGT opened at $4.95 on Thursday. The firm has a fifty day simple moving average of $5.23 and a two-hundred day simple moving average of $7.33. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $12.61. The firm has a market capitalization of $563.59 million, a PE ratio of -2.00 and a beta of 1.91.

Hedge Funds Weigh In On Cogent Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in COGT. Barclays PLC boosted its position in shares of Cogent Biosciences by 124.8% in the 3rd quarter. Barclays PLC now owns 175,684 shares of the technology company’s stock worth $1,897,000 after purchasing an additional 97,541 shares in the last quarter. New York State Common Retirement Fund raised its stake in Cogent Biosciences by 10.5% during the fourth quarter. New York State Common Retirement Fund now owns 23,102 shares of the technology company’s stock valued at $180,000 after buying an additional 2,200 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Cogent Biosciences by 9.7% during the third quarter. JPMorgan Chase & Co. now owns 64,828 shares of the technology company’s stock valued at $700,000 after buying an additional 5,720 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Cogent Biosciences in the fourth quarter worth $81,000. Finally, Vanguard Group Inc. grew its stake in shares of Cogent Biosciences by 7.3% in the fourth quarter. Vanguard Group Inc. now owns 6,133,380 shares of the technology company’s stock worth $47,840,000 after acquiring an additional 418,975 shares during the last quarter.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.